155 related articles for article (PubMed ID: 12148568)
1. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
Achen MG; Williams RA; Baldwin ME; Lai P; Roufail S; Alitalo K; Stacker SA
Growth Factors; 2002 Jun; 20(2):99-107. PubMed ID: 12148568
[TBL] [Abstract][Full Text] [Related]
2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
3. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
4. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract][Full Text] [Related]
6. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.
Stacker SA; Caesar C; Baldwin ME; Thornton GE; Williams RA; Prevo R; Jackson DG; Nishikawa S; Kubo H; Achen MG
Nat Med; 2001 Feb; 7(2):186-91. PubMed ID: 11175849
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
8. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
Baldwin ME; Catimel B; Nice EC; Roufail S; Hall NE; Stenvers KL; Karkkainen MJ; Alitalo K; Stacker SA; Achen MG
J Biol Chem; 2001 Jun; 276(22):19166-71. PubMed ID: 11279005
[TBL] [Abstract][Full Text] [Related]
9. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
10. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
Thelen A; Scholz A; Benckert C; von Marschall Z; Schröder M; Wiedenmann B; Neuhaus P; Rosewicz S; Jonas S
Int J Cancer; 2008 Jun; 122(11):2471-81. PubMed ID: 18338756
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
12. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
13. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
14. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
15. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Feng Y; Wang W; Hu J; Ma J; Zhang Y; Zhang J
Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
[TBL] [Abstract][Full Text] [Related]
16. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
Harris NC; Davydova N; Roufail S; Paquet-Fifield S; Paavonen K; Karnezis T; Zhang YF; Sato T; Rothacker J; Nice EC; Stacker SA; Achen MG
J Biol Chem; 2013 Mar; 288(12):8176-8186. PubMed ID: 23404505
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
Mu J; Abe Y; Tsutsui T; Yamamoto N; Tai XG; Niwa O; Tsujimura T; Sato B; Terano H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1996 Sep; 87(9):963-71. PubMed ID: 8878460
[TBL] [Abstract][Full Text] [Related]
18. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]